TrovaGene Inc (NASDAQ: TROV) is having a great start to the trading session this morning, trading up more than 18% after announcing positive preclinical data further validating its work with Onvansertib. TrovaGene is a company that I’ve followed closely. If you’re unfamiliar with their work, consider reading my full report here.
Nonetheless, the data that was released today not only helps to validate the work that the company is doing with Onvansertib, it serves to validate my bullish opinion on the stock. Let’s dive in:
TROV Announces Positive Onvansertib Data
In a press release issued this morning, TrovaGene issued a clinical update, sharing preclinical data surrounding its lead clinical candidate,